Caffeine protects Alzheimer's mice against cognitive impairment and reduces brain β-amyloid production

Neuroscience

Volumn 142, Issue 4, 2006, Pages 941-952

  Arendash, G W ^a,b   Schleif, W ^a,b   Rezai Zadeh, K ^c   Jackson, E K ^d   Zacharia, L C ^d   Cracchiolo, J R ^a,b   Shippy, D ^a,b   Tan, J ^c  

^a Research Institute   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

adenosine; BACE; learning; memory; PS1; transgenic mice

Indexed keywords

ADENOSINE A1 RECEPTOR; ADENOSINE A2A RECEPTOR; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; BETA SECRETASE; CAFFEINE; PRESENILIN 1;

ALZHEIMER DISEASE; ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN LEVEL; COFFEE; COGNITIVE DEFECT; CONCENTRATION RESPONSE; HIPPOCAMPUS; LONGITUDINAL STUDY; MALE; MENTAL TASK; MOUSE; NERVE CELL CULTURE; NEUROPHARMACOLOGY; NEUROPROTECTION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN SYNTHESIS INHIBITION; RECEPTOR DENSITY; RECOGNITION; TRANSGENIC MOUSE; WORKING MEMORY;

ADENOSINE; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; BRAIN; CAFFEINE; CELL LINE, TUMOR; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; MEMORY DISORDERS; MEMORY, SHORT-TERM; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEUROPROTECTIVE AGENTS; NEUROPSYCHOLOGICAL TESTS; PEPTIDE FRAGMENTS; PRESENILIN-1; RECEPTORS, PURINERGIC P1; TREATMENT OUTCOME;

EID: 33750984544     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2006.07.021     Document Type: Article

References (32)

1. Acquas E., Tanda G., and DiChiara G. Differential effects of caffeine on dopamine and acetylcholine transmission in brain areas of drug-naïve and caffeine pretreated rats. Neuropsychopharmacology 27 (2002) 182-193
2. Arendash G.W., Lewis J., Leighty R.E., McGowan E., Cracchiolo J.R., Hutton M., and Garcia M.F. Multi-metric behavioral comparison of APPsw and P301L models for Alzheimer's disease: linkage of poorer cognitive performance to tau pathology in forebrain. Brain Res 1012 (2004) 29-41
3. Cleary J.P., Walsh D.M., Hofmeister J.J., Shankar G.M., Kuskowski M.A., Selkoe D.J., and Ashe K.H. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci 8 (2005) 79-84
4. Comery T.A., Martone R.L., Aschmies S., Atchison K.P., Diamantidis G., Gong X., Zhou H., Kreft A.F., Pangalos M.N., Sonnenberg-Reines J., Jacobsen J.S., and Marquis K. Acute γ-secretase inhibition improves contextual fear conditioning in the Tg2576 mouse model of Alzheimer's disease. J Neurosci 25 (2005) 8898-8902
5. Conlay L.A., Connat J.A., deBros F., and Wurtman R. Caffeine alters plasma adenosine levels. Nature 389 (1997) 136
6. 2A receptor blockade of beta-amyloid neurotoxicity. Br J Pharmacol 138 (2003) 1207-1209
7. Fisone G., Borgkvist A., and Usiello A. Caffeine as a psychomotor stimulant: mechanism of action. Cell Mol Life Sci 61 (2004) 857-872
8. Fredholm B., Battig K., Holmen J., Nehlig A., and Zvartau E. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev 51 (1999) 83-133
9. Gandhi S., Refolo L.M., and Sambamurti K. Amyloid precursor protein compartmentalization restricts beta-amyloid production: therapeutic targets based on BACE compartmentalization. J Mol Neurosci 24 (2004) 137-143
10. Hameleers P.A., van Boxtel M.P., Hogervorst E., Riedel W.J., Houx P.J., Buntinz F., and Jolles J. Habitual caffeine consumption and its relation to memory, attention, planning capacity and psychomotor performance across multiple age groups. Hum Psychopharmacol 15 (2000) 573-581
11. Higdon J.V., and Frei B. Coffee and health: a review of recent human research. Critical Rev Food Sci Nutrition 46 (2006) 101-123
12. Inoue M., Yoshimi I., Sobue T., and Tsugane S. Influence of coffee drinking on subsequent risk of hepatocellular carcinoma: A prospective study in Japan. J Natl Cancer Inst 97 (2005) 293-300
13. Jarvis M.J. Does caffeine intake enhance absolute levels of cognitive performance?. Psychopharmacology 110 (1993) 45-52
14. Jensen M.T., Mottin M.D., Cracchiolo J.R., Leighty R.E., and Arendash G.W. Lifelong immunization with human β-amyloid (1-42) protects Alzheimer's transgenic mice against cognitive impairment throughout aging. Neuroscience 130 (2005) 667-684
15. Kayed R., Brambilla E., Sanvito F., Roccatagliata L., Olivieri S., Bergami A., Pluchino S., Uccelli A., Comi G., and Martino G. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300 (2003) 486-489
16. Klatsky A.L., Morton C., Udaltsova N., and Friedman G.D. Coffee, cirrhosis, and transaminase enzymes. Arch Intern Med 166 (2006) 1190-1195
17. Klyubin I., Walsh D.M., Lemere C.A., Cullen W.K., Shankar G.M., Betts V., Spooner E.T., Jiang L., Anwyl R., Selkoe D.J., and Rowan M.J. Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo. Nat Med 11 (2005) 556-561
18. Korkotian E., and Segal M. Release of calcium from stores alters the morphology of dendritic spines in cultured hippocampal neurons. Proc Natl Acad Sci U S A 96 (1999) 12068-12072
19. Leighty R.E., Nilsson L.N.G., Potter H., Costa D.A., Low M.A., Bales K.R., Paul S.M., and Arendash G.W. Use of multimetric statistical analysis to characterize and discriminate between the performance of four Alzheimer's transgenic mouse lines differing in Aβ deposition. Behav Brain Res 153 (2004) 107-121
20. Maia L., and de Mendonca A. Does caffeine intake protect from Alzheimer's disease?. Eur J Neurol 9 (2002) 377-382
21. Molinengo L., Scordo I., and Pastorello B. Action of caffeine, L-PIA and their combination on memory retention in the rat. Life Sci 54 (1994) 1247-1250
22. Paris D., Quadros A., Humphrey J., Patel N., Crescentini R., Crawford F., and Mullan M. Nilvadipine antagonizes both A-beta vasoactivity in isolated arteries, and the reduced cerebral blood flow in APPsw transgenic mice. Brain Res 999 (2004) 53-61
23. Phillis J.W. Adenosine and adenine nucleotides as regulators of cerebral blood flow: roles of acidosis, cell swelling, and KATP channels. Crit Rev Neurobiol 16 (2004) 237-270
24. Rezai-Zadeh K., Shytle D., Sun N., Mori T., and Tan J. Green tea epigallocatechin-3-gallate (EGCG) modulates amyloid precursor protein cleavage and reduces cerebral amyloidosis in Alzheimer transgenic mice. J Neurosci 25 (2005) 8807-8814
25. Ross G.W., Abbott R.D., Petrovitch H., Moren DM Grandinetti A., Tung K.H., Tanner C.M., Masaki K.H., Blanchette P.L., Curb J.D., Popper J.D., and White L.R. Association of coffee and caffeine intake with the risk of Parkinson's disease. JAMA 20 (2000) 2674-2679
26. Salazar-Martinez E., Willet W.C., Ascherio A., Manson J.E., Leitzmann M.F., Stampfer M.J., and Hu F.B. Coffee consumption and risk for type 2 diabetes mellitus. Ann Intern Med 140 (2004) 1-8
27. 2A receptor antagonists in animal models of Parkinson's disease. Neurology 61 Suppl 6 (2003) S55-S61
28. Tanaka H., Nakazawa K., Arima M., and Iwasaki W. Caffeine and its dimethylxanthines and fetal cerebral development in rat. Brain Dev 6 (1984) 355-361
29. van Boxtel M.P., Schmitt J.A., Bosma H., and Jolles J. The effects of habitual caffeine use on cognitive change: a longitudinal perspective. Pharmacol Biochem Behav 75 (2003) 921-927
30. Von Lubitz D.K., Paul I.A., Bartus R.T., and Jacobson K.A. Effects of chronic administration of adenosine A1 receptor agonist and antagonist on spatial learning and memory. Eur J Pharmacol 249 (1993) 271-280
31. Westerman M.A., Cooper-Blacketer D., Mariash A., Kotilinek L., Kawarabayashi T., Younkin L.H., Carlson G.A., Younkin S.G., and Ashe K.H. The relationship between Aβ and memory in the Tg2576 mouse model of Alzheimer's disease. J Neurosci 22 (2002) 1858-1867
32. Winkelmayer W.C., Stampfer M.J., Willett W.C., and Curhan G.C. Habitual caffeine intake and the risk of hypertension in women. JAMA 294 (2005) 2330-2335